Cell Surface Markers Market

In 2023, the market for cell surface markers was estimated to be worth USD 0.88 billion. The market for cell surface markers is expected to expand at a compound annual growth rate (CAGR) of 5.34% from 2023 to 2033, from USD 0.94 billion in 2024 to USD 1.48 billion by 2033.  The primary factors propelling market expansion are the growing global trend toward reducing healthcare costs and the development of healthcare technology.

Market Trends:

Increasing applications in research and diagnostics are driving the market growth.

The growing use of cell surface markers in various research and diagnostic applications worldwide is driving the market's compound annual growth rate (CAGR).  In research and diagnostics, cell surface markers are essential because they make it possible to identify, describe, and isolate particular cell populations.  The need for cell surface markers is increasing in a number of research domains, including immunology, cancer, stem cell research, and drug discovery, as our knowledge of cellular functions and disease mechanisms expands.  Cell surface indicators are also used in clinical diagnostics to track treatment outcomes and identify particular cell types and disease signs.  Cell surface marker analysis can help with disease diagnosis and prognosis in diagnostic settings.  Clinicians can determine the severity of a disease, distinguish between normal and aberrant cell populations, and forecast patient outcomes by looking at the expression profiles of particular cell surface markers.  This data supports personalized medicine methodologies by enabling customized treatment plans based on the unique characteristics of each patient.  All things considered, cell surface markers offer vital information on cellular identity, function, and disease-related alterations, making them indispensable instruments in research and diagnosis.

New methods for detecting and analyzing cell surface markers are being developed as a result of technological developments.  These developments include the application of sophisticated mass spectrometry, imaging, flow cytometry, and molecular biology methods.  These technologies provide more accurate and thorough cell surface marker profiling by providing enhanced sensitivity, multiplexing capabilities, and high-throughput analysis.  For example, a study that was published in Scientific Reports demonstrates that point-of-care prediction of patient response to different cancer medications can be made possible by the quick qualitative evaluation of surface markers on cancer cells.  The observation and study of cell surface markers at the cellular and subcellular levels has been made easier by developments in imaging technologies.  High-resolution imaging capabilities are provided by methods like confocal, super-resolution, and live-cell imaging, which make it possible to see the distribution, localization, and interactions of cell surface markers in three dimensions in real time.

High-throughput screening of cell surface markers has been made possible by technological improvements, allowing for the quick identification and characterization of many markers.  In order to find new cell surface markers and their functional significance, researchers can screen huge libraries of antibodies or probe sets against particular cell types using high-throughput screening platforms such antibody arrays and next-generation sequencing-based techniques.

Considerable progress in the study and use of cell surface markers is being fueled by the increased focus on precision medicine.  The goal of precision medicine is to customize care for each patient according to their distinct traits, including molecular profiles.  When it comes to finding biomarkers for customized treatments, cell surface indicators are essential.  Cell surface indicators linked to certain diseases, therapy response, and patient stratification are found and verified by researchers.  These indicators facilitate the creation of tailored treatments and aid in directing therapeutic choices.  Tests or assays known as companion diagnostics are created in conjunction with particular treatments to determine which individuals are most likely to benefit from them.  For companion diagnostics, cell surface markers are useful biomarkers.  To guarantee targeted therapy selection and maximize therapeutic outcomes, pharmaceutical companies are progressively integrating companion diagnostics based on cell surface markers into clinical trials and drug development procedures.  Immunotherapies, such as CAR-T cell treatments and immune checkpoint inhibitors, have completely changed the way cancer is treated.  In immune profiling, cell surface markers are essential for identifying immune cell groups, evaluating their functional state, and forecasting how well a treatment will work.  Finding cell surface indicators to forecast immunotherapy response, direct treatment selection, and track treatment efficacy is the main goal of ongoing research.

Segmentation Analysis:

By Product Analysis:

The market segmentation for cell surface markers includes PCR arrays and antibodies based on the product.  The market was led by the antibody category, which generated 0.27 billion, or 66.42% of total sales.  Antibodies are essential for researching and identifying cell surface indicators.

By Application Analysis:

Research and clinical are included in the market segmentation for cell surface markers based on application.  In 2022, the market was led by the research category, which generated approximately 72.58% (0.29 billion) of total revenue.  The growth of public-private collaborations for cell surface marker-based research is responsible for the segment's expansion.

By Source Analysis:

According to the report, mice and rats are included in the market segmentation for cell surface markers.  Because mice-based cell surface markers are so affordable, the mice category accounted for approximately 72.67% (0.291 billion) of the market.  Over the course of the projected period, the rat category is anticipated to increase at the fastest rate.

By Cell Type Analysis:

Based on cell type, the cell surface markers market segmentation comprises T cells, B cells, and NK cells.  Due to the increased use of T cells in research and diagnostic procedures, the T cells category accounted for approximately 46.82% (0.19 billion) of the market.  Throughout the projected period, the category of NK cells is anticipated to develop at the fastest rate.

By Region Analysis:

North America, Europe, Asia-Pacific, and the Rest of the World are the regions for which the study offers market information.  The market for cell surface markers will be dominated by North America due to the large number of cell and molecular biology research projects conducted there.

The second-largest market share is held by the cell surface markers industry in Europe.  Many factors, including as improvements in research, diagnostics, and the pharmaceutical sector, are credited with the market's expansion.  Furthermore, the market is anticipated to expand as a result of continuous advancements in cell surface markers and their uses.

From 2023 to 2032, the Asia-Pacific cell surface markers market is anticipated to expand at the quickest compound annual growth rate (CAGR).  This is a result of improvements in healthcare facilities and the sharp rise in the number of elderly people.

Key Companies:

• Bio-Rad Laboratories Ltd.

• Abbot

• Siemens Healthcare Private Limited

• Beckman Coulter Inc.

• Hoffman-La Roche Ltd

• Nihon Kohden Corporation

• Thermo Fisher Scientific

• BD Biosciences

• Abcam PLC

• Qiagen

• Danaher

• Genscript

• Merk KGaA

• Biolegend

• Cell Signalling Technology Inc.

• Bio-Techne

Industry Developments:

• December 2020 In overseas markets, Nihon Kohden launched MEK-1305 Celltac α+, an Automated Hematology and ESR Analyzer.

• December 2020 Abcam PLC announced opening a 16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a crucial new site for its specialist cell engineering team.

• In December 2019, Neuro-sys SAS company entered into a partnership agreement with Sciomis GmbH to collaboratively develop solution for neurodegenerative disorders. Sciomis has expertise in biomarker discovery. This platform of the company will help Neuro-sys SAS for developing the solution.

• In 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of Becton, Dickinson and Company. This will be integrated into the Life Sciences Solutions segment of Thermo Fisher.

• In 2018, Abcam entered into an exclusive license agreement with Roche. Under this agreement, the product portfolio of Spring Bioscience Corporation has been licensed to Abcam for research use only (RUO) applications.

• In 2018, QIAGEN opened its new shared service center in Manila—QIAGEN Business Services (QBS). QBS will provide services related to supply chain management, customer care, accounting, technical services, and other sales support activities to QIAGEN'S global operations.

Report Segmentations:

By Product

• Antibody

• PCR Array

By Application

• Research

• Clinical

By Source

• Mice

• Rat

By Cell Type

• T Cells

• B Cells

• NK Cells

By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa